This is a promotional website intended for healthcare professionals in the UK and Ireland only.
Back to Events

11th October 2023 6:00PM BST - Virtual

BRUKINSA®▼ (zanubrutinib): A BTK inhibitor with a difference – Shaping the future of CLL treatment in Scotland 

This live virtual meeting brought together expert clinicians to discuss BRUKINSA, a next-generation BTK inhibitor, as a treatment option for patients with CLL.  

Topics included clinical evidence supporting the use of BRUKINSA, patient case studies, the use of BRUKINSA in the NHS, and concluded with a panel-led Q&A session. 

On-demand video content from this meeting will be available soon.  



Dr Mark Rafferty

Consultant Haematologist, Beatson West of Scotland Cancer Centre

Dr Rafferty is a Consultant in Clinical Experimental Haematology at the Beatson West of Scotland Cancer Centre and an Honorary Clinical Senior Lecturer at the University of Glasgow School of Medicine. He has a specialist interest in clinical trials in haemato-oncology and acts as Principal Investigator or Co-Investigator across a number of clinical trials in CLL at the Beatson centre. He is also active in the Beatson regional flow cytometry diagnostic service.

Dr Renata Walewska

Consultant Haematologist, UH Dorset NHS Foundation Trust, Chair, UK CLL, England

Dr Walewska has been a Consultant Haematologist at the Royal Bournemouth Hospital since 2010. Since March 2019 she has chaired the UK CLL Forum. In addition, she is part of the writing committee that updated the national BSH CLL guidelines and is an invited clinical advisor to the Evidence Review Group for NICE appraisals.

Dr Talha Munir

Consultant Haematologist, Leeds Teaching Hospitals NHS Trust, England

Dr Munir has worked in the Leeds NHS trust since 2014 as Consultant Haematologist. His main clinical and research interests are in CLL and paroxysmal nocturnal haemoglobinuria (PNH). He is one of the PNH consultants working in the PNH National Service, a sub-investigator for the NCRI CLL clinical trials and he is involved in multiple studies at Leeds Teaching Hospital.

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

October 2023 [1023-BRU-PRC-088 ]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not